4.4 Article

Is Axonal Degeneration a Key Early Event in Parkinson's Disease?

期刊

JOURNAL OF PARKINSONS DISEASE
卷 6, 期 4, 页码 703-707

出版社

IOS PRESS
DOI: 10.3233/JPD-160881

关键词

Parkinson disease; axons; animal disease models; autophagy; review; dopaminergic neurons; substantia nigra pars compacta; synapses; axonal transport; retrograde degeneration

向作者/读者索取更多资源

Recent research suggests that in Parkinson's disease the long, thin and unmyelinated axons of dopaminergic neurons degenerate early in the disease process. We organized a workshop entitled 'Axonal Pathology in Parkinson's disease', on March 23rd, 2016, in Cleveland, Ohio with the goals of summarizing the state-of-the-art and defining key gaps in knowledge. A group of eight research leaders discussed new developments in clinical pathology, functional imaging, animal models, and mechanisms of degeneration including neuroinflammation, autophagy and axonal transport deficits. While the workshop focused on PD, comparisons were made to other neurological conditions where axonal degeneration is well recognized.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Clinical Neurology

Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study

Tanya Simuni, Liz Uribe, Hyunkeun Ryan Cho, Chelsea Caspell-Garcia, Christopher S. Coffey, Andrew Siderowf, John Q. Trojanowski, Leslie M. Shaw, John Seibyl, Andrew Singleton, Arthur W. Toga, Doug Galasko, Tatiana Foroud, Duygu Tosun, Kathleen Poston, Daniel Weintraub, Brit Mollenhauer, Caroline M. Tanner, Karl Kieburtz, Lana M. Chahine, Alyssa Reimer, Samantha J. Hutten, Susan Bressman, Kenneth Marek, Vanessa Arnedo, Adrienne Clark, Mark Fraiser, Catherine Kopil, Sohini Chowdhury, Todd Sherer, Nichole Daegele, Christina Salerno, Cynthia Casaceli, Ray Dorsey, Renee Wilson, Sugi Mahes, Karen Crawford, Paola Casalin, Giulia Malferrari, Mali GaniWeisz, Avi Orr-Urtreger, Thomas Montine, Chris Baglieri, Amanda Christini, David Russell, Nabila Dahodwala, Nir Giladi, Stewart Factor, Penelope Hogarth, David Standaert, Robert Hauser, Joseph Jankovic, Marie Saint-Hilaire, Irene Richard, David Shprecher, Hubert Fernandez, Katrina Brockmann, Liana Rosenthal, Paolo Barone, Alberto Espay, Dominic Rowe, Karen Marder, Anthony Santiago, Shu-Ching Hu, Stuart Isaacson, Jean-Christophe Corvol, Javiar Ruiz Martinez, Eduardo Tolosa, Yen Tai, Marios Politis, Debra Smejdir, Linda Rees, Karen Williams, Farah Kausar, Karen Williams, Whitney Richardson, Diana Willeke, Shawnees Peacock, Barbara Sommerfeld, Alison Freed, Katrina Wakeman, Courtney Blair, Stephanie Guthrie, Leigh Harrell, Christine Hunter, Cathi-Ann Thomas, Raymond James, Grace Zimmerman, Victoria Brown, Jennifer Mule, Ella Hilt, Kori Ribb, Susan Ainscough, Misty Wethington, Madelaine Ranola, Helen Mejia Santana, Juliana Moreno, Deborah Raymond, Krista Speketer, Stephanie Carvalo, Ioana Croitoru, Alicia Garrido, Laura Marie Payne, Veena Viswanth, Lawrence Severt, Maurizio Facheris, Holly Soares, Mark A. Mintun, Jesse Cedarbaum, Peggy Taylor, Kevin Biglan, Emily Vandenbroucke, Zulfiqar Haider Sheikh, Baris Bingol, Tanya Fischer, Pablo Sardi, Remi Forrat, Alastair Reith, Jan Egebjerg, Gabrielle Ahlberg Hillert, Barbara Saba, Chris Min, Robert Umek, Joe Mather, Susan De Santi, Anke Post, Frank Boess, Kirsten Taylor, Igor Grachev, Andreja Avbersek, Pierandrea Muglia, Kaplana Merchant, Johannes Tauscher

LANCET NEUROLOGY (2020)

Editorial Material Clinical Neurology

Movement Disorders in the World of COVID-19

A. Jon Stoessl, Kailash P. Bhatia, Marcelo Merello

MOVEMENT DISORDERS (2020)

Article Clinical Neurology

Recommendation of the 5th Canadian Consensus Conference on the diagnosis and treatment of dementia

Zahinoor Ismail, Sandra E. Black, Richard Camicioli, Howard Chertkow, Nathan Herrmann, Robert Laforce, Manuel Montero-Odasso, Kenneth Rockwood, Pedro Rosa-Neto, Dallas Seitz, Saskia Sivananthan, Eric E. Smith, Jean-Paul Soucy, Isabelle Vedel, Serge Gauthier

ALZHEIMERS & DEMENTIA (2020)

Editorial Material Clinical Neurology

Immunotherapy for Parkinson's disease: stay tuned

A. Jon Stoessl

LANCET NEUROLOGY (2020)

Review Neurosciences

GDNF and Parkinson's Disease: Where Next? A Summary from a Recent Workshop

Roger A. Barker, Anders Bjorklund, Don M. Gash, Alan Whone, Amber Van Laar, Jeffrey H. Kordower, Krystof Bankiewicz, Karl Kieburtz, Mart Saarma, Sigrid Booms, Henri J. Huttunen, Adrian P. Kells, Massimo S. Fiandaca, A. Jon Stoessl, David Eidelberg, Howard Federoff, Merja H. Voutilainen, David T. Dexter, Jamie Eberling, Patrik Brundin, Lyndsey Isaacs, Leah Mursaleen, Eros Bresolin, Camille Carroll, Alasdair Coles, Brian Fiske, Helen Matthews, Codrin Lungu, Richard K. Wyse, Simon Stott, Anthony E. Lang

JOURNAL OF PARKINSONS DISEASE (2020)

Letter Clinical Neurology

COVID-19 and selective vulnerability to Parkinson's disease

Alexandra Pavel, Danielle K. Murray, A. Jon Stoessl

LANCET NEUROLOGY (2020)

Editorial Material Clinical Neurology

2021: Looking Forward

A. Jon Stoessl

MOVEMENT DISORDERS (2021)

Article Neurosciences

Weeding through the haze: a survey on cannabis use among people living with Parkinson's disease in the US

Megan P. Feeney, Danny Bega, Benzi M. Kluger, A. Jon Stoessl, Christiana M. Evers, Rebeca De Leon, James C. Beck

Summary: A survey found that approximately a quarter of people with Parkinson's disease in the United States had used cannabis in the past six months, primarily to alleviate non-motor symptoms such as anxiety, pain, and sleep disorders. Lack of scientific evidence supporting the efficacy of cannabis for PD has led to cautious attitudes towards its use among patients.

NPJ PARKINSONS DISEASE (2021)

Review Clinical Neurology

Dopamine Receptors in Parkinson's Disease: A Meta-Analysis of Imaging Studies

Valtteri Kaasinen, Tero Vahlberg, A. Jon Stoessl, Antonio P. Strafella, Angelo Antonini

Summary: This study conducted a systematic review and meta-analysis on the expression of dopamine receptors in PD, PSP, and MSA, revealing differences in binding values of dopamine receptors among patients with different diseases.

MOVEMENT DISORDERS (2021)

Review Clinical Neurology

Emerging Neuroimaging Biomarkers Across Disease Stage in Parkinson Disease A Review

Trina Mitchell, Stephane Lehericy, Shannon Y. Chiu, Antonio P. Strafella, A. Jon Stoessl, David E. Vaillancourt

Summary: Imaging biomarkers for different stages of Parkinson's disease are crucial for monitoring progression in clinical trials and improving clinical care. This review highlights the importance of considering disease stage when implementing diagnostic and progression biomarkers in both clinical trials and clinical care settings.

JAMA NEUROLOGY (2021)

Editorial Material Clinical Neurology

What's New at the Journal in 2022

A. Jon Stoessl

MOVEMENT DISORDERS (2022)

Article Multidisciplinary Sciences

Cortical morphology predicts placebo response in multiple sclerosis

Mariya V. Cherkasova, Jessie F. Fu, Michael Jarrett, Poljanka Johnson, Shawna Abel, Roger Tam, Alexander Rauscher, Vesna Sossi, Shannon Kolind, David K. B. Li, A. Dessa Sadovnick, Lindsay Machan, J. Marc Girard, Francois Emond, Reza Vosoughi, Anthony Traboulsee, A. Jon Stoessl

Summary: Despite limited therapeutic effects, certain multiple sclerosis patients demonstrated a transient improvement in health-related quality of life, indicating a placebo response. The study found that placebo responders had higher lesion activity and exhibited a different cortical architecture compared to non-responders.

SCIENTIFIC REPORTS (2022)

Editorial Material Clinical Neurology

WHAT'S NEW IN THE JOURNAL THIS MONTH : A PATIENT'S PERSPECTIVE

A. Jon Stoessl

MOVEMENT DISORDERS (2022)

Article Clinical Neurology

Serotonergic System Impacts Levodopa Response in Early Parkinson's and Future Risk of Dyskinesia

Jessie F. Fu, Michele Matarazzo, Jessamyn McKenzie, Nicole Neilson, Nasim Vafai, Katie Dinelle, Andre C. Felicio, Martin J. McKeown, A. Jon Stoessl, Vesna Sossi

Summary: The study found that the serotonergic system contributes to dopamine release and increases the risk for motor complications in early Parkinson's disease. Moreover, this contribution fails to provide sustained therapeutic advantage in early disease.

MOVEMENT DISORDERS (2021)

Article Neuroimaging

Novel data-driven, equation-free method captures spatio-temporal patterns of neurodegeneration in Parkinson's disease: Application of dynamic mode decomposition to PET

Jessie Fanglu Fu, Ivan S. Klyuzhin, Martin J. McKeown, A. Jon Stoessl, Vesna Sossi

NEUROIMAGE-CLINICAL (2020)

暂无数据